Tackling brain cancer is complicated, but groundbreaking new research could help add another tool to the cancer-fighting arsenal.
Roivant strikes another deal, selling dermatology spinoff to Organon in deal worth $1.2 billion
Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of its subsidiaries to pharma company Organon in a deal worth